Stevanato Group announced a collaboration with leading Contract Development and Manufacturing Organization or CDMO, Recipharm. Under the agreement, Stevanato Group will lend its manufacturing experience to support the development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers. As part of this collaboration, Stevanato Group will provide and manufacture its glass pre-fillable syringe Alba assembled with the Integrated Spray Module or ISMTM, of Recipharm’s soft mist inhaler technology, the Pre-Filled Syringe Inhaler or PFSITM. "By leveraging Stevanato Group’s integrated capabilities, from plastic injection molding and assembly capabilities to comprehensive scientific and analytical support services, we will be able to offer a turnkey solution, and accelerate and de-risk our pharmaceutical customers’ development programs. This is particularly true for novel inhaled biological products."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on STVN:
- Stevanato Group price target raised to $27 from $21 at Wells Fargo
- Stevanato Group price target raised to $30 from $22 at Citi
- Stevanato Group sees 2023 adjusted EPS EUR0.58-EUR0.62 vs. EUR0.56 in 2022
- Stevanato Group reports Q4 adjusted EPS EUR0.18 vs. EUR0.17 last year
- Stevanato teams with Transcoject to provide polymer options for pharma